Pierre Chatelain

9.8k total citations
237 papers, 7.7k citations indexed

About

Pierre Chatelain is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Cellular and Molecular Neuroscience. According to data from OpenAlex, Pierre Chatelain has authored 237 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Molecular Biology, 70 papers in Endocrinology, Diabetes and Metabolism and 48 papers in Cellular and Molecular Neuroscience. Recurrent topics in Pierre Chatelain's work include Growth Hormone and Insulin-like Growth Factors (53 papers), Receptor Mechanisms and Signaling (42 papers) and Neuropeptides and Animal Physiology (27 papers). Pierre Chatelain is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (53 papers), Receptor Mechanisms and Signaling (42 papers) and Neuropeptides and Animal Physiology (27 papers). Pierre Chatelain collaborates with scholars based in France, Belgium and Germany. Pierre Chatelain's co-authors include Michel Gillard, Patrick Wilton, Jean Christophe, Kerstin Albertsson‐Wikland, Patrick Robberecht, Michael B. Ranke, Wayne S. Cutfield, B. B. Fuks, R. Massingham and Magalì Waelbroeck and has published in prestigious journals such as The Lancet, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Pierre Chatelain

232 papers receiving 7.4k citations

Peers

Countries citing papers authored by Pierre Chatelain

Since Specialization

Citations

This map shows the geographic impact of Pierre Chatelain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pierre Chatelain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pierre Chatelain more than expected).

Fields of papers citing papers by Pierre Chatelain

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pierre Chatelain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pierre Chatelain. The network helps show where Pierre Chatelain may publish in the future.

Co-authorship network of co-authors of Pierre Chatelain

This figure shows the co-authorship network connecting the top 25 collaborators of Pierre Chatelain. A scholar is included among the top collaborators of Pierre Chatelain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pierre Chatelain. Pierre Chatelain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Pediatric Phase 2 Data Demonstrate that TransCon hGH Has an Anti-hGH Immunogenic Profile that is Comparable to Daily hGH 2016 ·(unknown), Susanne Pihl, Pierre Chatelain, Michael Beckert	1
2	Olfactory receptors: from basic science to applications in flavors and fragrances. 2010 ·(unknown), Françoise Wilkin, (unknown), (unknown), Pierre Chatelain	1
3	Improvement in Adult Height after Growth Hormone Treatment in Adolescents with Short Stature Born Small for Gestational Age: Results of a Randomized Controlled Study 2003 ·The Journal of Clinical Endocrinology & Metabolism ·Jean‐Claude Carel, Pierre Chatelain, P Rochiccioli, Jean‐Louis Chaussain	105
4	Clinical and Endocrine Characteristics in Atypical and Classical Growth Hormone Insensitivity Syndrome 2001 ·Hormone Research in Paediatrics ·Christine Burren, Katie A. Woods, Steven J. Rose, (unknown), David A. Price, U. Heinrich, (unknown), Maryam Razzaghy‐Azar, (unknown), Patricia Crock, P Rochiccioli, N Yordam, Michael B. Ranke, Pierre Chatelain, M A Preece, Ron G. Rosenfeld, Martin O. Savage	47
5	Retard de croissance intra-utérin, ses conséquences à la naissance, dans l’enfance et à long terme 2001 ·Bulletin de l Académie Nationale de Médecine ·Bernard L. Salle, Pierre Chatelain, Marc Nicolino, Olivier Claris	4
6	Prediction of Long-Term Response to Recombinant Human Growth Hormone in Turner Syndrome: Development and Validation of Mathematical Models 2000 ·The Journal of Clinical Endocrinology & Metabolism ·Michael B. Ranke, Anders Lindberg, Pierre Chatelain, Patrick Wilton, Wayne S. Cutfield, Kerstin Albertsson‐Wikland, David A. Price	115
7	Multiple Hormone Resistance in Short Children Born with Intrauterine Growth Retardation? 1998 ·Hormone Research in Paediatrics ·Pierre Chatelain, Marc Nicolino, (unknown), B Salle, Jean‐Louis Chaussain	35
8	Low dose linomide in Type I juvenile diabetes of recent onset: a randomised placebo-controlled double blind trial 1998 ·Diabetologia ·R. Coutant, Paul Landais, Myriam Rosilio, Christin Johnsen, N. Lahlou, Pierre Chatelain, Jean‐Claude Carel, Johnny Ludvigsson, Christian Boîtard, Pierre Bougnères	62
9	Long term results of growth hormone treatment in France in children of short stature: population, register based study 1997 ·BMJ ·(unknown), M Letrait, Jean‐Claude Carel, (unknown), Pierre Chatelain, P Rochiccioli, J L Chaussain, (unknown)	58
10	Three years of GH treatment in Turner's syndrome: complex effect of GH dosage on growth parameters 1996 ·Clinical Endocrinology ·A.-M. Bertrand, J L Chaussain, Bernard Job, Raffaella Mariani, (unknown), R Rappaport, (unknown), Pierre Chatelain	3
11	Interaction of the antiarrhythmic agents SR 33589 and amiodarone with the β‐adrenoceptor and adenylate cyclase in rat heart 1995 ·British Journal of Pharmacology ·Pierre Chatelain, (unknown), (unknown), (unknown), M. Clinet	63
12	Effects of irbesartan (SR 47436/BMS-186295) on angiotensin II-induced pressor responses in the pithed rat: potential mechanisms of action 1995 ·European Journal of Pharmacology ·B. Christophe, (unknown), Catherine Cazaubon, Dino Nisato, A Manning, Pierre Chatelain	32
13	Effect of SR 47436, a novel angiotensin II AT1 receptor antagonist, on human vascular smooth muscle cells in vitro 1994 ·European Journal of Pharmacology ·Jean‐Marc Herbert, (unknown), Frédérique Dol, Paul Schaeffer, Catherine Cazaubon, Dino Nisato, Pierre Chatelain	45
14	In vitro characterization of a novel Ca2+ entry blocker: SR 33805 1993 ·European Journal of Pharmacology Molecular Pharmacology ·Pierre Chatelain, M. Clinet, Peter Polster, B. Christophe, A Manning	13
15	Fantofarone (SR 33557): effect on post-ischaemic functional recovery in perfused rat hearts 1992 ·European Journal of Pharmacology ·A Manning, (unknown), Pierre Chatelain	2
16	[Hypotensive effect of a new calcium antagonist, SR 33557 in conscious rats]. 1990 ·PubMed ·C Lacour, (unknown), G Galindo, Pierre Chatelain, Dino Nisato	2
17	SR 33557, a novel calcium entry blocker. I. In vitro isolated tissue studies. 1990 ·Journal of Pharmacology and Experimental Therapeutics ·Peter Polster, B. Christophe, (unknown), (unknown), Pierre Chatelain	23
18	Effect of Acute Intravenous Growth Hormone-Releasing Factor on Plasma Prolactin in Short Children and Patients with Growth Hormone Deficiency 1985 ·Hormone Research ·Pierre Chatelain, G. Sassolas, (unknown), (unknown), (unknown), Bruno Claustrat, M David, (unknown)	3
19	Species variations and physiopathology of VIP-PHI-secretin receptors in heart and lung 1983 ·Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) ·Jean Christophe, Pierre Chatelain, Magalì Waelbroeck, Patrick Robberecht	8
20	Characterization of Secretin and Vasoactive Intestinal Peptide Receptors in Rat Pancreatic Plasma Membranes Using the Native Peptides, Secretin-(7–27) and Five Secretin Analogues 1982 ·Digestion ·Patrick Robberecht, Magalì Waelbroeck, Michel Noyer, Pierre Chatelain, Philippe De Neef, Wolfgang König, Jean Christophe	45

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact